Titan Pharmaceuticals Inc. (TTNP) Posts Top-line Clinical Trial Results for Opioid Addiction Treatment
Titan Pharmaceuticals Inc. today released positive results from its phase 3 clinical study of Probuphine™ to evaluate the safety and efficacy of the drug in treating patients with opioid dependence. The drug was developed using Titan's continuous drug delivery system ProNeura. The company reported statistically significant results from the study, which confirmed the efficacy of Probuphine compared to placebo. Probuphine also met a key trial objective by demonstrating non-inferiority to treatment with the approved drug Suboxone®. In addition, the trial demonstrated that Probuphine was well tolerated, with an overall safety profile similar to previous study results. Based on the results,…